Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name	Generic Name	Therapeutic Area	Recommendation Type	Project Status	Date Submission Received	Date Recommendation Issued Sort ascending
Abstral	Fentanyl citrate	Pain, breakthrough cancer pain	Do not list	Complete	Jun 30, 2011	Dec 16, 2011
Twynsta	Telmisartan/ Amlodipine	Hypertension	List	Complete	Aug 23, 2011	Dec 16, 2011
Brilinta	Ticagrelor	Acute coronary syndromes	Do not list	Complete	Jun 1, 2011	Dec 16, 2011
XGEVA	Denosumab	Prevention of skeletal-related events due to bone metastases from solid tumours	List with clinical criteria and/or conditions	Complete	Jun 6, 2011	Nov 16, 2011
Aclasta	Zoledronic acid	Osteoporosis	List with clinical criteria and/or conditions	Complete	Jul 20, 2011	Nov 16, 2011
Gilenya	Fingolimod	Multiple Sclerosis, relapsing-remitting	List with clinical criteria and/or conditions	Complete	May 10, 2011	Nov 16, 2011
Victrelis	Boceprevir	Hepatitis C, chronic	List with clinical criteria and/or conditions	Complete	May 3, 2011	Oct 24, 2011
Revolade	Eltrombopag olamine	Chronic immune thrombocytopenic purpura	Do not list	Complete	Apr 26, 2011	Oct 24, 2011
Toctino	Alitretinoin	Eczema	List with clinical criteria and/or conditions	Complete	May 6, 2011	Oct 24, 2011
Victoza	Liraglutide	Diabetes mellitus, Type 2	Do not list	Complete	Nov 29, 2010	Sep 28, 2011

Last Updated : May 15, 2024